Sometimes it seems that retina research moves at a snail’s pace, but science is steadily moving toward those treatments and cures that will keep our eyes healthy. This is an update on four therapeutics just around the corner for treatment of age-related macular degeneration (AMD). Of the hundreds of ongoing clinical trials for both wet [Read More]
Author: Dan Roberts
Neovascularization May Slow Progression of Geographic Atrophy
Neovascularization, or new blood vessel growth, is a restorative function of the body that assists in healing. When it occurs in the retina, however, it can lead to vision loss. In age-related macular degeneration (AMD) the photoreceptor cells weaken over time. In about 10 to 15 percent of AMD patients, the inflammatory system sends new [Read More]
Don’t Blame Everything On Your Macula
So your sight is slowly diminishing, and your ophthalmologist told you that nothing could be done. They said that the cells in the very center of your retina (the macula) are degenerating, and gradual loss of clear eyesight is to be expected. Still, they want to see you at least once a year unless you [Read More]
Latest statistics on prevalence of blindness and low vision worldwide
The Vision Loss Expert Group (VLEG) has published new findings about four areas of interest to the blind and low vision community. The report provides timely updates on acuity measurement standards, prevalence of global cases, and prevalence of types of blindness and vision impairment. For those who are interested in statistics, here are summaries of [Read More]
Newest Sustained-Release Anti-VEGF Drug in Trials
EyePoint Pharmaceuticals, Inc. announced on January 28, 2021 that the first patient has been dosed in their Phase 1 clinical trial of EYP-1901. EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration (wAMD). It is the newest of several sustained delivery drugs under study, this one promising to extend [Read More]